WebZYNTEGLO is a one-time gene therapy to treat beta-thalassemia in adult and pediatric patients who require regular red blood cell (RBC) transfusions β 0 /β 0: no beta-globin is produced Non-β 0 /β 0: a reduced amount of beta-globin is produced *In the phase 3 studies, the safety and efficacy of ZYNTEGLO was studied in patients aged 4–34 years. WebFeb 15, 2024 · In 2024, Bluebird Bio pulled Zynteglo from Europe after withdrawing it from Germany, where health officials rejected its target price of $1.8 million. But the U.S. landscape may be changing:...
investors & media - bluebird bio, Inc.
WebMay 5, 2024 · Now the Institute for Clinical and Economic Review (ICER) has given Zynteglo its figurative blessing, stating that the product is cost-effective, even at the price of $2.1 million per treatment.... WebOct 21, 2024 · Bluebird bio on Thursday said it will withdraw from market a rare disease gene therapy recently approved in Europe as the company winds down operations … city of chino hills utility billing office
bluebird bio Receives EC Approval for SKYSONA™ (elivaldogene …
WebApr 14, 2024 · Gene therapies are typically designed to “cure” a disease by replacing or fixing a damaged gene. Bluebird’s therapy, which is listed under the brand name … WebJul 21, 2024 · About bluebird bio, Inc. bluebird bio is pioneering gene therapy with purpose. From our Cambridge, Mass., headquarters, we’re developing gene and cell therapies for severe genetic diseases and ... Web20 hours ago · Two gene therapies up for approval this year for sickle cell disease could be cost effective in some cases at a $2 million price point, based on a draft evidence report published by the Institute for Clinical and Economic Review (ICER). Released on April 12, the report focuses on bluebird bio’s lovotibeglogene autotemcel and Vertex … don e smith obituary